ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 39808248

The Current Role of Circulating Tumor DNA in the Management of Pancreatic Cancer.

Cox M and 2 others. J Gastrointest Cancer, 2025. Cited by 6 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. The Current Role of Circulating Tumor DNA in the Management of Pancreatic Cancer. Papers, record 39808248. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39808248

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The Current Role of Circulating Tumor DNA in the Management of Pancreatic Cancer.
PubMed
Journal
J Gastrointest Cancer
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
1.39, provisional
iCite
Revised in PubMed
2026-11-01
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cox MMadison
2Vitello DJDominic J
3Chawla AAkhil

Source PubMed

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Circulating Tumor DNAMajor topic
Pancreatic NeoplasmsMajor topic
Biomarkers, TumorMajor topic
Carcinoma, Pancreatic DuctalMajor topic
Humans
Prognosis

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
5R38CA245095National Institues of HealthR38CA245095PubMed

Source NIH RePORTER

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References72

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134,805,152Clinical Impact of Molecular Subtyping of Pancreatic Cancer.Front Cell Dev Biol2021https://conductscience.org/library/papers/34805152PubMed
229,416,754Targeted deep sequencing of circulating tumor DNA in metastatic pancreatic cancer.Oncotarget2018https://conductscience.org/library/papers/29416754PubMed
335,883,626Crucial Role of Oncogenic KRAS Mutations in Apoptosis and Autophagy Regulation: Therapeutic Implications.Cells2022https://conductscience.org/library/papers/35883626PubMed
433,437,802Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review.Ann Transl Med2020https://conductscience.org/library/papers/33437802PubMed
526,154,128Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients.Nat Commun2015https://conductscience.org/library/papers/26154128PubMed
634,547,082Pancreatic Cancer: A Review.JAMA2021https://conductscience.org/library/papers/34547082PubMed
730,339,520Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing.J Clin Oncol2018https://conductscience.org/library/papers/30339520PubMed
838,637,634Targeting KRAS in cancer.Nat Med2024https://conductscience.org/library/papers/38637634PubMed
925,596,178The acinar regulator Gata6 suppresses KrasG12V-driven pancreatic tumorigenesis in mice.Gut2016https://conductscience.org/library/papers/25596178PubMed
1034,830,853Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors.Cancers (Basel)2021https://conductscience.org/library/papers/34830853PubMed

1 to 10 of 72

See all 72 references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42,730,833Overcoming cancer resistance in pancreatic cancer: toward dynamic precision oncology.Mol Biol Rep2026https://conductscience.org/library/papers/42730833PubMed
42,226,668Dynamic Prognostic Nutritional Index With Circulating Tumor DNA Predicts Survival in Localized Pancreatic Ductal Adenocarcinoma.J Surg Oncol2026https://conductscience.org/library/papers/42226668PubMed
40,806,185Advances in the Management of Pancreatic Cancer: Current Strategies and Emerging Therapies.Int J Mol Sci2025https://conductscience.org/library/papers/40806185PubMed
40,559,099Molecular Biomarkers for the Diagnosis and Prognostication of Pancreatic Ductal Adenocarcinoma.J Pers Med2025https://conductscience.org/library/papers/40559099PubMed
40,511,613Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma.J Natl Cancer Inst2025https://conductscience.org/library/papers/40511613PubMed

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39808248

GET https://conductscience.org/api/papers/v1/39808248/references?page=2

API referenceFor AI assistants